Delayed cerebral ischaemia after subarachnoid haemorrhage: Looking beyond vasospasm

British Journal of Anaesthesia

Volumn 109, Issue 3, 2012, Pages 315-329

  Rowland, M J ^a   Hadjipavlou, G ^a   Kelly, M ^a   Westbrook, J ^a   Pattinson, K T S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cerebral vasospasm; cortical spreading depression; delayed cerebral ischaemia; early brain injury; microthrombosis; subarachnoid haemorrhage

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CLAZOSENTAN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENTANYL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INHALATION ANESTHETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM; MAGNESIUM SULFATE; NIMODIPINE; PRAVASTATIN; PROPOFOL; REMIFENTANIL; SIMVASTATIN; TAK 044;

ARTERY CONSTRICTION; AUTOPSY; BRAIN ARTERY; BRAIN ARTERY ANEURYSM RUPTURE; BRAIN EDEMA; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN PERFUSION; BRAIN VASOSPASM; CAROTID ARTERIOGRAPHY; CEREBRAL AUTOREGULATION; COMPUTER ASSISTED TOMOGRAPHY; DELAYED CEREBRAL ISCHEMIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; GENETIC ASSOCIATION; GENETIC RISK; HEMODILUTION; HEMODYNAMICS; HUMAN; INFLAMMATION; INJURY SEVERITY; INTRACRANIAL PRESSURE; MICROTHROMBUS; NERVE FIBER DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEDATION; SPREADING CORTICAL DEPRESSION; SUBARACHNOID HEMORRHAGE; VASOCONSTRICTION;

EID: 84865224256     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aes264     Document Type: Review

References (149)

1. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke 1997; 28: 491-9
2. Passier PECA, Visser-Meily JMA, Rinkel GJE, Lindeman E, Post MWM. Life satisfaction and return to work after aneurismal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis 2011; 20: 324-9
3. Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke 2010; 41: e519-36
4. Scott RB, Eccles F, Molyneux AJ, Kerr RSC, Rothwell PM, Carpenter K. Improved cognitive outcomes with endovascular coiling of ruptured intracranial aneurysms: neuropsychological outcomes from the International Subarachnoid Aneurysm Trial (ISAT). Stroke 2010; 41: 1743-7
5. Dorsch NW, King MT. A review of cerebral vasospasm in aneurismal subarachnoid haemorrhage Part I: incidence and effects. J Clin Neurosci 1994; 1: 19-26
6. Kassell N, Torner J, Clarke Haley E Jr, et al. The international cooperative study on the timing of aneurysm surgery. J Neurosurg 1990; 73: 18-36
7. Vergouwen MDI, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke 2010; 41: 2391-5
8. Diringer MN, Bleck TP, Claude Hemphill J, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care 2011; 15: 211-40
9. Beadles C. Aneurisms of the larger cerebral arteries. Brain 1907; 30: 285-336
10. Robertson EG. Cerebral lesions due to intracranial aneurysms. Brain 1949; 72 (Pt 2): 150-85
11. Ecker A, Riemenschneider P. Arteriographic demonstration of spasm of the intracranial arteries, with special reference to saccular arterial aneurysms. J Neurosurg 1951; 8: 660-7
12. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980; 6: 1-9
13. Weir B, Grace M, Hansen J, Rothberg C. Time course of vasospasm in man. J Neurosurg 1978; 48: 173-8
14. Bederson JB, Levy AL, Ding WH, et al. Acute vasoconstriction after subarachnoid hemorrhage. Neurosurgery 1998; 42: 352-60
15. Fergusen S, Macdonald RL. Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2007; 60: 658-67
16. Vergouwen MDI, Etminan N, Ilodigwe D, Macdonald RL. Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2011; 31: 1545-53
17. Dorsch N. A clinical review of cerebral vasospasm and delayed ischaemia following aneurysm rupture. Acta Neurochir Suppl 2011; 110 (Pt 1): 5-6
18. Naidech AM, Drescher J, Tamul P, Shaibani A, Batjer HH, Alberts MJ. Acute physiological derangement is associated with early radiographic cerebral infarction after subarachnoid haemorrhage. J Neurol Neurosurg Psychiatr 2006; 77: 1340-4
19. Vergouwen MDI, Ilodigwe D, Macdonald RL. Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects. Stroke 2011; 42: 924-9
20. Minhas PS, Menon DK, Smielewski P, et al. Positron emission tomographic cerebral perfusion disturbances and transcranial Doppler findings among patients with neurological deterioration after subarachnoid hemorrhage. Neurosurgery 2003; 52: 1017-24
21. Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poorgrade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg 1988; 68: 505-17
22. Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J. Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review. Neurology 1998; 50: 876-83
23. Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008; 39: 3015-21
24. Polin RS, Coenen VA, Hansen CA, et al. Efficacy of transluminal angioplasty for the management of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 2000; 92: 284-90
25. Broderick JP, Brott TG, Duldner JE, Tomsick T, Leach A. Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. Stroke 1994; 25: 1342-7
26. Kusaka G, Ishikawa M, Nanda A, Granger DN, Zhang JH. Signaling pathways for early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2004; 24: 916-25
27. Swift DM, Solomon RA. Subarachnoid hemorrhage fails to produce vasculopathy or chronic blood flow changes in rats. Stroke 1988; 19: 878-82
28. Aoki T, Nishimura M. The development and the use of experimental animal models to study the underlying mechanisms of CA formation. J Biomed Biotechnol 2011; 2011: 1-10
29. Sobey CG. Cerebrovascular dysfunction after subarachnoid haemorrhage: novel mechanisms and directions for therapy. Clin Exp Pharmacol Physiol 2001; 28: 926-9
30. Nornes H. The role of intracranial pressure in the arrest of hemorrhage in patients with ruptured intracranial aneurysm. J Neurosurg 1973; 39: 226-34
31. Grote E, Hassler W. The critical first minutes after subarachnoid hemorrhage. Neurosurgery 1988; 22: 654
32. Bederson JB, Germano IM, Guarino L. Cortical blood flow and cerebral perfusion pressure in a new non-craniotomy model of subarachnoid hemorrhage in the rat. Stroke 1995; 26: 1086-91
33. Nornes H, Magnaes B. Intracranial pressure in patients with ruptured saccular aneurysm. J Neurosurg 1972; 36: 537-47
34. Asano T, Sano K. Pathogenetic role of no-reflow phenomenon in experimental subarachnoid hemorrhage in dogs. J Neurosurg 1977; 46: 454-66
35. Schwartz AY, Masago A, Sehba FA, Bederson JB. Experimental models of subarachnoid hemorrhage in the rat: a refinement of the endovascular filament model. J Neurosci Methods 2000; 96: 161-7
36. Claassen J, Carhuapoma J, Kreiter K, Du E, Connolly E, Mayer S. Global cerebral edema after subarachnoid hemorrhage: frequency, predictors, and impact on outcome. Stroke 2002; 33: 1225
37. Keep RF, Andjelkovic AV, Stamatovic SM, Shakui P, Ennis SR. Ischemia-induced endothelial cell dysfunction. Acta Neurochir Suppl 2005; 95: 399-402
38. Rätsep T, Asser T. Cerebral hemodynamic impairment after aneurysmal subarachnoid hemorrhage as evaluated using transcranial Doppler ultrasonography: relationship to delayed cerebral ischemia and clinical outcome. J Neurosurg 2001; 95: 393-401
39. Lang EW, Diehl RR, Mehdorn HM. Cerebral autoregulation testing after aneurysmal subarachnoid hemorrhage: the phase relationship between arterial blood pressure and cerebral blood flow velocity. Crit Care Med 2001; 29: 158-63
40. Aries MJH, Elting JW, De Keyser J, Kremer BPH, Vroomen PCAJ. Cerebral autoregulation in stroke: a review of transcranial Doppler studies. Stroke 2010; 41: 2697-704
41. Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovasc Brain Metab Rev 1990; 2: 161-92
42. Ayer R, Zhang J. Connecting the early brain injury of aneurismal subarachnoid hemorrhage to clinical practice. Turk Neurosurg 2010; 20: 159-66
43. Osuka K, Suzuki Y, Tanazawa T, et al. Interleukin-6 and development of vasospasm after subarachnoid haemorrhage. Acta Neurochir 1998; 140: 943-51
44. Mathiesen T, Edner G, Ulfarsson E, Andersson B. Cerebrospinal fluid interleukin-1 receptor antagonist and tumor necrosis factor-alpha following subarachnoid hemorrhage. J Neurosurg 1997; 87: 215-20
45. Leao A. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944; 7: 359
46. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994; 117 (Pt 1): 199-210
47. Dohmen C, Sakowitz OW, Fabricius M, et al. Spreading depolarizations occur in human ischemic stroke with high incidence. Ann Neurol 2008; 63: 720-8
48. Strong AJ, Fabricius M, Boutelle MG, et al. Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke 2002; 33: 2738-43
49. Dreier JP, Major S, Manning A, et al. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain 2009; 132 (Pt 7): 1866-81
50. Leao A. Pial circulation and spreading depression of activity in the cerebral cortex. J Neurophysiol 1944; 7: 391-6
51. Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. J Cereb Blood Flow Metab 2011; 31: 17-35
52. Lauritzen M. Long-lasting reduction of cortical blood flow of the brain after spreading depression with preserved autoregulation and impaired CO2 response. J Cereb Blood Flow Metab 1984; 4: 546-54
53. Dreier JP, Woitzik J, Fabricius M, et al. Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations. Brain 2006; 129 (Pt 12): 3224-37
54. Shin HK, Dunn AK, Jones PB, Boas DA, Moskowitz MA, Ayata C. Vasoconstrictive neurovascular coupling during focal ischemic depolarizations. J Cereb Blood Flow Metab 2006; 26: 1018-30
55. Bosche B, Graf R, Ernestus R-I, et al. Recurrent spreading depolarizations after subarachnoid hemorrhage decreases oxygen availability in human cerebral cortex. Ann Neurol 2010; 67: 607-17
56. Woitzik J, Dreier JP, Hecht N, et al. Delayed cerebral ischemia and spreading depolarization in absence of angiographic vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2012; 32: 203-12
57. Hirashima Y, Nakamura S, Endo S, Kuwayama N, Naruse Y, Takaku A. Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage. Neurochem Res 1997; 22: 1249-55
58. Frijns CJM, Fijnheer R, Algra A, van Mourik JA, van Gijn J, Rinkel GJE. Early circulating levels of endothelial cell activation markers in aneurysmal subarachnoid haemorrhage: associations with cerebral ischaemic events and outcome. J Neurol Neurosurg Psychiatr 2006; 77: 77-83
59. Hirashima Y, Nakamura S, Suzuki M, et al. Cerebrospinal fluid tissue factor and thrombin-antithrombin III complex as indicators of tissue injury after subarachnoid hemorrhage. Stroke 1997; 28: 1666-70
60. Ikeda K, Asakura H, Futami K, Yamashita J. Coagulative and fibrinolytic activation in cerebrospinal fluid and plasma after subarachnoid hemorrhage. Neurosurgery 1997; 41: 344-9
61. Peltonen S, Juvela S, Kaste M, Lassila R. Hemostasis and fibrinolysis activation after subarachnoid hemorrhage. J Neurosurg 1997; 87: 207-14
62. Romano JG, Forteza AM, Concha M, et al. Detection of microemboli by transcranial Doppler ultrasonography in aneurysmal subarachnoid hemorrhage. Neurosurgery 2002; 50: 1026-30; discussion 1030-1
63. Suzuki S, Kimura M, Souma M, Ohkima H, Shimizu T, Iwabuchi T. Cerebral microthrombosis in symptomatic cerebral vasospasm- A quantitative histological study in autopsy cases. Neurol Med Chir (Tokyo) 1990; 30: 309-16
64. Stein SC, Browne KD, Chen X-H, Smith DH, Graham DI. Thromboembolism and delayed cerebral ischemia after subarachnoid hemorrhage: an autopsy study. Neurosurgery 2006; 59: 781-7
65. Neil-Dwyer G, Lang DA, Doshi B, Gerber CJ, Smith PW. Delayed cerebral ischaemia: the pathological substrate. Acta Neurochir 1994; 131: 137-45
66. Vernieri F, Pasqualetti P, Matteis M, et al. Effect of collateral blood flow and cerebral vasomotor reactivity on the outcome of carotid artery occlusion. Stroke 2001; 32: 1552-8
67. Romero JR, Pikula A, Nguyen TN, Nien YL, Norbash A, Babikian VL. Cerebral collateral circulation in carotid artery disease. Curr Cardiol Rev 2009; 5: 279-88
68. Liebeskind D. Collateral circulation. Stroke 2003; 34: 2279-84
69. Toni D, Fiorelli M, Bastianello S, et al. Acute ischemic strokes improving during the first 48 hours of onset: predictability outcome, and possible mechanisms. A comparison with early deteriorating strokes. Stroke 1997; 28: 10-4
70. Bang OY, Saver JL, Buck BH, et al. Impact of collateral flow on tissue fate in acute ischaemic stroke. J Neurol Neurosurg Psychiatr 2008; 79: 625-9
71. Bang OY, Saver JL, Alger JR, et al. Determinants of the distribution and severity of hypoperfusion in patients with ischemic stroke. Neurology 2008; 71: 1804-11
72. Shaw MD, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM. Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: A report by the Steering Committee on behalf of the UK/Netherlands/ Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg 2000; 93: 992-7
73. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurismal subarachnoid hemorrhage: results of a randomized, doubleblind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005; 103: 9-17
74. Barth M, Capelle H-H, Münch E, et al. Effects of the selective endothelin A (ET(A)) receptor antagonist clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage-preliminary results from a randomized clinical series. Acta Neurochir 2007; 149: 911-8
75. Actelion website. Available from our-company/news-and-events/index.page? newsId=1446888. Last accessed 18 May 2011
76. Clinicaltrials.gov website. Available from ct2/show/study/NCT00940095? term=Vasospasm&rank=14#locn. Last accessed 18 May 2011
77. Wong GKC, Poon WS. Clazosentan for patients with subarachnoid haemorrhage: lessons learned. Lancet Neurol 2011; 10: 871
78. Chen G, Tariq A, Ai J, et al. Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats. Brain Res 2011; 1392: 132-9
79. Peroutka SJ, Allen GS. Calcium channel antagonist binding sites labeled by 3H-nimodipine in human brain. J Neurosurg 1983; 59: 933-7
80. Cheung JY, Bonventre JV, Malis CD, Leaf A. Calcium and ischemic injury. N Engl J Med 1986; 314: 1670-6
81. Kazda S, Towart R. Nimodipine: a new calcium antagonistic drug with a preferential cerebrovascular action. Acta Neurochir 1982; 63: 259-65
82. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. Br Med J 1989; 298: 636-42
83. Dorhout Mees SM, Rinkel GJE, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007; CD000277
84. 2+ rise induced by oxygen/glucose deprivation in cortical neurons. Stroke 1998; 29: 196-201; discussion 202
85. Horn J, Limburg M. Calcium antagonists for ischemic stroke: A systematic review. Stroke 2001; 32: 570-6
86. Langham J, Goldfrad C, Teasdale G, Shaw D, Rowan K. Calcium channel blockers for acute traumatic brain injury. Cochrane Database Syst Rev 2003; CD000565
87. Vergouwen MDI, Vermeulen M, de Haan RJ, Levi M, Roos YBWEM. Dihydropyridine calcium antagonists increase fibrinolytic activity: a systematic review. J Cereb Blood Flow Metab 2006; 27: 1293-308
88. Dreier JP, Windmü ller O, Petzold G, Lindauer U, Einhäupl KM, Dirnagl U. Ischemia triggered by red blood cell products in the subarachnoid space is inhibited by nimodipine administration or moderate volume expansion/hemodilution in rats. Neurosurgery 2002; 51: 1457-65
89. Denny-Brown D. The treatment of recurrent cerebrovascular symptoms and the question of 'vasospasm'. Med Clin North Am 1951; 35: 1457-74
90. Kosnik EJ, Hunt WE. Postoperative hypertension in the management of patients with intracranial arterial aneurysms. J Neurosurg 1976; 45: 148-54
91. Kassell NF, Peerless SJ, Durward QJ, Beck DW, Drake CG, Adams HP. Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery 1982; 11: 337-43
92. Rinkel GJE, Feigin VL, Algra A, van Gijn J. Circulatory volume expansion therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2004; CD000483
93. Dankbaar JW, Slooter AJ, Rinkel GJ, Schaaf ICVD. Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review. Crit Care 2010; 14: R23
94. van den Bergh WM, Algra A, van der Sprenkel JWB, Tulleken CAF, Rinkel GJE. Hypomagnesemia after aneurysmal subarachnoid hemorrhage. Neurosurgery 2003; 52: 276-81
95. van den Bergh WM, Zuur JK, Kamerling NA, et al. Role of magnesium in the reduction of ischemic depolarization and lesion volume after experimental subarachnoid hemorrhage. J Neurosurg 2002; 97: 416-22
96. van der Hel WS, van den Bergh WM, Nicolay K, Tulleken KA, Dijkhuizen RM. Suppression of cortical spreading depressions after magnesium treatment in the rat. Neuroreport 1998; 9: 2179-82
97. Wong GKC, Poon WS, Chan MTV, et al. Plasma magnesium concentrations and clinical outcomes in aneurysmal subarachnoid hemorrhage patients: post hoc analysis of intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage trial. Stroke 2010; 41: 1841-4
98. Wong GK, Boet R, Poon WS, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage: an updated systemic review and meta-analysis. Crit Care 2011; 15: R52
99. Peters SAE, Palmer MK, Grobbee DE, et al. C-reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med 2010; 268: 155-61
100. Ota H, Eto M, Kano MR, et al. Induction of endothelial nitric oxide synthase, sirt1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler Thromb Vasc Biol 2010; 30: 2205-11
101. Szapary L, Horvath B, Marton Z, et al. Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia. CNS Drugs 2004; 18: 165-72
102. Cheng G, Wei L, Zhi-Dan S, Shi-Guang Z, Xiang-Zhen L. Atorvastatin ameliorates cerebral vasospasm and early brain injury after subarachnoid hemorrhage and inhibits caspasedependent apoptosis pathway. BMC Neurosci 2009; 10: 7
103. Merlo L, Cimino F, Scibilia A, et al. Simvastatin administration ameliorates neurobehavioral consequences of subarachnoid hemorrhage in the rat. J Neurotrauma 2011; 28: 2493-501
104. Lynch JR, Wang H, Mcgirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke 2005; 36: 2024-6
105. Chou SH-Y, Smith EE, Badjatia N, et al. A randomized, double-blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage. Stroke 2008; 39: 2891-3
106. Vergouwen M, Meijers J, Geskus R, et al. Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial. J Cereb Blood Flow Metab 2009; 29: 1444-53
107. Tseng M-Y, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke 2005; 36: 1627-32
108. Vergouwen MDI, de Haan RJ, Vermeulen M, Roos YBWEM. Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke 2010; 41: e47-52
109. Chang C-Z, Wu S-C, Lin C-L, Hwang S-L, Howng S-L, Kwan A-L. Atorvastatin preconditioning attenuates the production of endothelin-1 and prevents experimental vasospasm in rats. Acta Neurochir 2010; 152: 1399-406
110. Parra A, Kreiter KT, Williams S, et al. Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurismal subarachnoid hemorrhage: a matched controlled cohort study. Neurosurgery 2005; 56: 476-84
111. Mcgirt MJ, Blessing R, Alexander MJ, et al. Risk of cerebral vasopasm after subarachnoid hemorrhage reduced by statin therapy: A multivariate analysis of an institutional experience. J Neurosurg 2006; 105: 671-4
112. Moskowitz SI, Ahrens C, Provencio JJ, Chow M, Rasmussen PA. Prehemorrhage statin use and the risk of vasospasm after aneurysmal subarachnoid hemorrhage. Surg Neurol 2009; 71: 311-7
113. Singhal AB, Topcuoglu MA, Dorer DJ, Ogilvy CS, Carter BS, Koroshetz WJ. SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage. Neurology 2005; 64: 1008-13
114. STASH Trial Website. Available from home.html. Last accessed 4 June 2011
115. van den Bergh WM, MASH Study Group, Algra A, et al. Randomized controlled trial of acetylsalicylic acid in aneurysmal subarachnoid hemorrhage: the MASH Study. Stroke 2006; 37: 2326-30
116. Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJE. Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007; CD006184
117. Libersan D, Khalil A, Dagenais P, et al. The low molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog. Cardiovasc Res 1998; 37: 656-66
118. Gikakis N, Khan MM, Hiramatsu Y, et al. Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation. Circulation 1996; 94 (9 Suppl.): II341-6
119. Xi G, Wagner KR, Keep RF, et al. Role of blood clot formation on early edema development after experimental intracerebral hemorrhage. Stroke 1998; 29: 2580-6
120. Jonas S, Sugimori M, Llinás R. Is low molecular weight heparin a neuroprotectant? Ann N Y Acad Sci 1997; 825: 389-93
121. Siironen J, Juvela S, Varis J, et al. No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial. J Neurosurg 2003; 99: 953-9
122. Wurm G, Tomancok B, Nussbaumer K, Adelwöhrer C, Holl K. Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo. Clin Neurol Neurosurg 2004; 106: 97-103
123. Roos YB, Rinkel GJ, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2000; CD001245
124. Amin-Hanjani S, Ogilvy CS, Barker FG II. Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis. Neurosurgery 2004; 54: 326-35
125. Starke RM, Kim GH, Komotar RJ, et al. Endothelial nitric oxide synthase gene single-nucleotide polymorphism predicts cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2008; 28: 1204-11
126. Khurana VG, Meissner I, Meyer FB. Update on genetic evidence for rupture-prone compared with rupture-resistant intracranial saccular aneurysms. Neurosurg Focus 2004; 17: E7
127. Ko NU, Rajendran P, Kim H, et al. Endothelial nitric oxide synthase polymorphism (-786T-.C) and increased risk of angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Stroke 2008; 39: 1103-8
128. Corder EH, Nicoll JA, Murray G, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-3
129. Teasdale GM, Nicoll JA, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997; 350: 1069-71
130. Alberts MJ, Graffagnino C, Khurana VG, et al. ApoE genotype and survival from intracerebral haemorrhage. Lancet 1995; 346: 575
131. McCarron MO, Muir KW, Nicoll JA, et al. Prospective study of apolipoprotein E genotype and functional outcome following ischemic stroke. Arch Neurol 2000; 57: 1480-4
132. Gao J, Wang H, Sheng H, et al. A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. Neurocrit Care 2006; 4: 25-31
133. Niskakangas T, Ohman J, Niemela M, Ilveskoski E, Kunnas TA, Karhunen PJ. Association of apolipoprotein E polymorphism with outcome after aneurysmal subarachnoid hemorrhage: a preliminary study. Stroke 2001; 32: 1181-4
134. Lanterna LA, Ruigrok Y, Alexander S, et al. Meta-analysis of APOE genotype and subarachnoid hemorrhage: clinical outcome and delayed ischemia. Neurology 2007; 69: 766-75
135. Juvela S, Siironen J, Lappalainen J. Apolipoprotein E genotype and outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg 2009; 110: 989-95
136. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14: 55-61
137. Pepe MG, Curtiss LK. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol 1986; 136: 3716-23
138. Piper RD, Lambert GA. Inhalational anesthetics inhibit spreading depression: relevance to migraine. Cephalalgia 1996; 16: 87-92
139. Kudo C, Nozari A, Moskowitz MA, Ayata C. The impact of anesthetics and hyperoxia on cortical spreading depression. Exp Neurol 2008; 212: 201-6
140. Kitahara Y, Taga K, Abe H, Shimoji K. The effects of anesthetics on cortical spreading depression elicitation and c-fos expression in rats. J Neurosurg Anesthesiol 2001; 13: 26-32
141. Thomson H, Harper NJ, Parkes A. Use of the AnaConDa anaesthetic delivery system to treat life-threatening asthma. Anaesthesia 2007; 62: 295-6
142. Wentlandt K, Samoilova M, Carlen PL, Beheiry El H. General anesthetics inhibit gap junction communication in cultured organotypic hippocampal slices. Anesth Analg 2006; 102: 1692-8
143. Sasaki R, Hirota K, Asahi T, Yamazaki M. The effects of thiopental on spreading depression induced by anoxia in the rat hippocampal slice in vitro. Hiroshima J Anaesth 2002; 38: 211-4
144. Hernándéz-Cáceres J, Macias-Gonzá lez R, Brozek G, Bures J. Systemic ketamine blocks cortical spreading depression but does not delay the onset of terminal anoxic depolarization in rats. Brain Res 1987; 437: 360-4
145. Sakowitz OW, Unterberg AW. Detecting and treating microvascular ischemia after subarachnoid hemorrhage. Curr Opin Crit Care 2006; 12: 103-11
146. Petzold A, Keir G, Kay A, Kerr M, Thompson EJ. Axonal damage and outcome in subarachnoid haemorrhage. J Neurol Neurosurg Psychiatr 2006; 77: 753-9
147. Fountas KN, Tasiou A, Kapsalaki EZ, et al. Serum and cerebrospinal fluid C-reactive protein levels as predictors of vasospasm in aneurysmal subarachnoid hemorrhage. Clinical article. Neurosurg Focus 2009; 26: E22
148. Sehba FA, Pluta RM, Zhang JH. Metamorphosis of subarachnoid hemorrhage research: from delayed vasospasm to early brain injury. Mol Neurobiol 2011; 43: 27-40
149. + is increased in the subarachnoid space. J Cereb Blood Flow Metab 1998; 18: 978-90